Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

Research analysts at Zacks Research cut their Q1 2025 EPS estimates for shares of GSK in a note issued to investors on ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven analysts ...

The pharmaceutical firm has followed several companies which have dropped diversity goals amid pressure from President Donald ...

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

Almost half of councils in England risk falling into bankruptcy without action to address a £4.6bn deficit amassed under a ...

One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale ...

“In tandem with fourth-quarter results that included a 3% pro forma sales decline and 10% adjusted operating margin, Hasbro ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The company might buy the shares directly or offer shareholders the option of tendering their shares at a fixed price. Share repurchases automatically increase the earnings per share (EPS ...